No. 23-788
Hope Medical Enterprises, Inc., dba Hope Pharmaceuticals v. Fagron Compounding Services, LLC, et al.
Tags: circuit-split drug-regulation federal-law federal-preemption food-and-drug-administration preemption state-law state-rights statutory-interpretation
Latest Conference:
2024-05-16
(distributed 2 times)
Question Presented (from Petition)
Whether the FDCA preempts state laws prohibiting the in-state sale of unapproved drugs whose sale is also prohibited as a matter of federal law by the FDCA.
Question Presented (AI Summary)
Whether the FDCA preempts state laws prohibiting the in-state sale of unapproved drugs whose sale is also prohibited as a matter of federal law by the FDCA
Docket Entries
2024-05-20
Petition DENIED.
2024-04-30
DISTRIBUTED for Conference of 5/16/2024.
2024-04-26
Reply of petitioner Hope Medical Enterprises, Inc. DBA Hope Pharmaceuticals filed. (Distributed)
2024-04-12
Brief of respondents Fagron Compounding Services, LLC, et al. in opposition filed.
2024-03-01
Motion to extend the time to file a response is granted and the time is extended to and including April 15, 2024. See Rule 30.1.
2024-02-29
Motion to extend the time to file a response from March 14, 2024 to April 13, 2024, submitted to The Clerk.
2024-02-13
Response Requested. (Due March 14, 2024)
2024-02-07
DISTRIBUTED for Conference of 2/23/2024.
2024-01-24
Waiver of right of respondents Fagron Compounding Services, LLC, et al. to respond filed.
2024-01-16
Petition for a writ of certiorari filed. (Response due February 21, 2024)
2023-12-17
Application (23A530) granted by Justice Kagan extending the time to file until January 16, 2024.
2023-12-07
Application (23A530) to extend the time to file a petition for a writ of certiorari from December 31, 2023 to January 16, 2024, submitted to Justice Kagan.
Attorneys
Fagron Compounding Services, LLC, et al.
Christopher Landau — Ellis George LLP, Respondent
Hope Medical Enterprises, Inc. DBA Hope Pharmaceuticals
Jeffrey S. Bucholtz — King & Spalding LLP, Petitioner